Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Labiana Health S.A. is a Spain-based pharmaceutical holding company specializing in the development, manufacturing, and marketing of medicines for both animal and human health. It offers a diverse portfolio including anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, vitamins, and sterile, lyophilized, and biological formats. Notable own-brand products feature Fosfomycin Trometamol under Fosfomicina Labiana for urinary infections. The company provides contract development and manufacturing organization (CDMO) services, regulatory support for global product registrations, and expertise in galenic, analytical, and formulation development, including bacterial vaccines. Operating through subsidiaries like Veterinarski Zavod Subotica in Serbia for biologicals and vaccines, and Zoleant Pharmaceuticals International in Turkey for niche generics and feed additives, it serves markets in Spain, the European Union, North America, and over 150 countries worldwide. With six production plants in Spain and Serbia, Labiana Health S.A. supports livestock productivity, human therapeutics, and the 'One Health' principle linking animal, human, and environmental well-being. Founded in 1958 and headquartered in Pozuelo de Alarcón, Madrid, it stands as a key player in veterinary pharmaceuticals and human sterile forms.
€6.50
+€0.00 (+0.00%)
EOD Jun 23, 2026 · Twelve Data
Operating margin is thin at 9.71%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 13.5% YoY with margins expanding 2.0pp. However, free cash flow softened 166%, worth monitoring whether this is timing or structural.
Free cash flow declined 166% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -€3M. The business is consuming cash, not generating it.
18.1x earnings. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€75M
▲ +13.5% YoY
Net Income (TTM)
€3M
▲ +1136.8% YoY
Op. Margin
9.71%
▲ +2.0pp YoY
ROIC
18.39%
▲ +8.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€3M
▼ -166.0% YoY
Op. Cash Flow (TTM)
€2M
▼ -64.7% YoY
Net Debt
€31M
Cash & Equiv.
€6M
3Y CAGR: +9.1%
Continue Research